ONCOLOGY REFERRAL FORM (A-T)

PHONE 888.370.1724 | **FAX** 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION													
Last Name	First Name	ne DOB			Gender □M □F L		Last 4 SSN		Primary Language				
Address		Cit		City				State		ZIP			
Email	Hom	Home Phone			Work Pho	one			Cell Phone				
Primary Contact Method (check	e □ Tex	☐ Text ☐ Email ☐ Primary Caregiver ☐ DO NOT CONTACT											
Primary Caregiver/Alt Contact Na	me (If applicable)		Alt Conta	ct Email					Alt Cor	ntact Phone			
PRESCRIBER INFORMATI	ON												
Name of Contact Sending Referral Title						Preferred	Contact Met	hod (check	one)	□ Email □ Pho	one 🗆 Fax		
Referral Contact Email		Office Phone Office Fax											
Practice / Facility Name		Prescriber Name / Specialty											
Address					City State Z								
Prescriber State License #	DEA #	NF	ગ #			Medi	edicaid UPIN #						
	* Pleas	se include a c	copy of the	e fron	t and back	k of insu	ırance ca	ard *					
CLINICAL INFORMATION	- Please include	applicable clir	ical chart n	otes									
Patient New to Therapy ☐ Yes ☐ No, Start Date of Current Therapy:							Dat	e Medicatio	cation Needed				
Treatment History or Failed Thera	apies (Please also attac	ch recent labs/clinic	cal notes)										
Sample/Starter Provided? ☐ No ☐ Yes, Provide Qty: Date Provided:					tient Height (c	m/in):	Weight		Date Obtained:				
Other/Concomitant Medications	(please list)												
Allergies □ NKDA □ Drug Alle	ergies (please list)												
Ship to Address ☐ Home ☐ P	rescriber's Office	Other (please list)											
ICD-10 Code	Description:			-									
PRESCRIPTION INFORMA	TION - Please Es	cribe if require	ed by state	law									
In order for a brand name pro	duct to be dispense	ed, the prescriber	r must handw	∕rite "Br									
or your state-specific required	d language to prohit	bit substitutions.	This form is i	not a va	lid prescripti	on form fo	or writing c	ontrolled n	nedicat	tions.			
ORAL ONCOLOGY AGENTS							1			T			
☐ Abiraterone Acetate ☐	Braftovi	☐ Fareston			□ Inrebic		☐ Mektovi			Rezurock			
Afinitor	Capecitabine	☐ Farydak	☐ Farydak		□ Jakafi		☐ Mercaptopurine			□ Rydapt			
☐ Afinitor Disperz	Daurismo	☐ Femara	☐ Femara		Kisqali		☐ Mesnex			☐ Scemblix			
□ Alkeran □	Emcyt	□ Gavreto	□ Gavreto		Kisqali + Femai	ra Co-Pack	ack			☐ Soltamox			
□ Anastrozole □	Erivedge	□ Gleevec	☐ Gleevec		Lapatinib		☐ Mylotarg			☐ Sorafenib			
□ Arimidex □	Erleada	☐ Gleostine	☐ Gleostine		Lenvima		□ Nilandron			☐ Sprycel			
□ Aromasin □	Erlotinib	☐ Hycamtir	☐ Hycamtin		Letrozole		□ Nilutamide			☐ Sunitinib Malate			
□ Besponsa □	Etoposide	☐ Hydroxyu	☐ Hydroxyurea		Leucovorin		□ Nolvadex			□ Sutent			
□ Bexarotene □	Everolimus	□ Ibrance	□ Ibrance		Leukeran		Odomzo			□ Tabrecta			
☐ Bicalutamide ☐	Everolimus Soluble	□ Imatinib	☐ Imatinib Mesylate		☐ Lorbrena		☐ Onureg		☐ Tafinlar				
□ Bosulif	Exemestane	□ Inlyta	□ Inlyta		Mekinist		☐ Piqray			□ Talzenna			
Dose:													
Directions:													
BMS REMS PRODUCTS													
REVLIMID*					Risk Category								
□ Take 1 capsule PO once daily. □ Take 1 capsule PO daily; days 1-21 of 28-day cycle. □ Other: □ QTY: 21 □ Other:				O Refills	□AI	☐ ADULT Female, NOT of Reproductive Potential							
				O Refills O Refills	□AI	☐ ADULT Female, Reproductive Potential ☐ ADULT Male							
THALOMID*				_	• 11011110	— □ Fe	☐ Female CHILD, NOT of Reproductive Potential ☐ Female CHILD, Reproductive Potential						
☐ Take 1 capsule PO once daily. QTY: 28					0 Refills		☐ Male CHILD						
☐ Other: QTY:					0 Refills		Celgene Auth #:						
POMALYST* □1 mg □2 mg □3 mg □4 mg					Date Issued:					_			
□ Take 1 capsule PO once daily, days 1-21 of 28-day cycle. QTY: 21 □ Other: QTY:				O Refills		Confirmation #: Date Issued:				_			
			QTY:		0 Refills		Date Issued:						
				_									
Prescriber Signature DAW (Dispense as Written)		Date			Supervising Physician Signature (where required I			required by	state lav	w) Date			
					Brand Necessary (must handwrite)					_			

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

ONCOLOGY REFERRAL FORM (T-Z)

PHONE 888.370.1724 | **FAX** 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION														
Last Name	First Name	First Name DOB			Gender □ M □ F Last		Last 4 SSN	t 4 SSN		Primary Language				
Address				City				State		ZII	P			
Email	Hoi	Home Phone				Work Phone					Cell Phone			
Primary Contact Method (check of	☐ Work Phone	e 🗆 Tex	Text □ Email □ Primary Caregiver □ DO NOT CONTACT											
Primary Caregiver/Alt Contact Na	me (If applicable)		Alt Conta	ct Email					Alt (Contact Ph	one			
PRESCRIBER INFORMATION	NC													
Name of Contact Sending Referra	I		Title			Prefe	erred Contact Me	ethod (chec	k one)	☐ Email	□ Pho	ne 🗆 Fax		
Referral Contact Email		Office Phone			C	Office Fa	X							
Practice / Facility Name		Prescriber Name / Specialty												
Address					ty				St	ate		ZIP		
Prescriber State License #	per State License # DEA #							Me	edicaid UPIN #					
	* Plea	se include a	copy of the	e fron	t and back	k of I	insurance c	ard *						
CLINICAL INFORMATION	- Please include	applicable cli	nical chart r	otes										
Patient New to Therapy ☐ Yes ☐ No, Start Date of Current Therapy:					Date Medication Needed									
Treatment History or Failed Thera	pies (Please also atta	ch recent labs/clin	cal notes)											
Sample/Starter Provided? ☐ No	Pa	atient Height (c	:m/in):	Weigh	nt (kg/lbs):		Date Ok	otained:						
Other/Concomitant Medications (please list)													
Allergies □ NKDA □ Drug Alle	rgies (please list)													
Ship to Address ☐ Home ☐ Pi	rescriber's Office	Other (please list)												
ICD-10 Code □ Code:	Description:													
PRESCRIPTION INFORMA	TION - Please E	scribe if requir	ed by state	law										
In order for a brand name pro- or your state-specific required										eations				
ORAL ONCOLOGY AGENTS	ranguage to prom		TIIIS TOTTI IS T	iot a va	ilia prescripti	OII IOI	ini ioi wiitiig	conti onec	rriedic	.ations.				
	Valada	□ Other:												
	Xeloda													
	Xtandi	☐ Other:												
	Yonsa	□ Other:												
	Zolinza	□ Other:												
	Zykadia	□ Other:												
	Zytiga	□ Other:												
	Other:	- Ctrici:												
-	Other:													
· ·	Other:													
	Other:													
			☐ Tablets ☐ 0	Capsules	□ Other:			Qty:		Re	fills:			
Directions:														
BMS REMS PRODUCTS														
REVLIMID* □ 2.5 mg □ 5 mg	ı □ 10 mg □ 15 mg	」 □ 20 mg □ 25	mg				Risk Category							
☐ Take 1 capsule PO once daily. ☐ Take 1 capsule PO daily; days 1-21 of 28-day cycle. ☐ Other:			QTY: 28 QTY: 21 QTY:		O Refills O Refills O Refills		☐ ADULT Fema ☐ ADULT Fema ☐ ADULT Male				ntial			
THALOMID* □ 50 mg □ 100	mg □150 mg □2	00 mg					☐ Female CHIL				itial			
☐ Take 1 capsule PO once daily.			QTY: 28				☐ Male CHILD							
Other: QTY:					0 Refills	Celgene Auth #: Date Issued:								
POMALYST*							Confirmation #:					-		
☐ Take 1 capsule PO once daily, da☐ Other:	nys 1-21 of 28-day cyc	le.	QTY: 21 QTY:		O Refills O Refills		Date Issued:					-		
Prescriber Signature DAW (Dispense as Written)		Date	Date			Supervising Physician Signature (where required by state law) Date								
		Date	Date		Brand Necessary (must handwrite)									

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.